Save Time, Save Resources, Save Lives.


Lawrence Livermore National Laboratory Publishes Report about ExcitePCR's FireflyDX Technologies

January 22, 2018

Earlier today, ExcitePCR's parent company (PositiveID) announced that Lawrence Livermore National Laboratory has completed an analysis and report of the FireflyDXTM real-time polymerase chain reaction (PCR) pathogen detection prototype.

A copy of the Lawrence Livermore National Laboratory Report can be found here.

About ExcitePCR


Read More

ExcitePCR Named “Major Player” by Questale in Report titled “Global POC Molecular Diagnostics Market Size, Status and Forecast 2022”

December 14, 2017

Pleasanton, Calif.  — For the first time, ExcitePCR has been recognized as a “major player” in the Point-of-Care/Point-of-Need (POC/PON) healthcare diagnostics marketplace.


Read More

ExcitePCR White Paper — PCR Unchained: The Coming Revolution in Field-based Pathogen Detection

October 24, 2017

Enclosed below is a digital version of ExcitePCR's first White Paper — "PCR Unchained: The Coming Revolution in Field-based Pathogen Detection."

This White Paper has been written for three primary purposes:

  • To provide a scientifically accurate yet basic introduction to the world of Pathogens — biological organisms that cause (or lead to)...

Read More

ExcitePCR Lauds New Report on “Defense of Animal Agriculture” Published Last Week by the Blue Ribbon Study Panel on Biodefense

October 23, 2017

Pleasanton, Calif. and Washington, D.C. — October 23, 2017 — ExcitePCR today applauded the timing, tenor and tenacity of a new Report titled “...

Read More ExcitePCR to launch RT pathogen detection system in 2018

October 11, 2017

ExcitePCR is to launch a real time pathogen detection system next year with targeted industries including the food and AgBio marketplace.

For the balance of the story, please visit



Read More

ExcitePCR Announces its Board of Advisors

September 26, 2017

Pleasanton, Calif. — September 26, 2017 — ExcitePCR today announced it has formed a Board of Advisors, with Dr. R. Paul Schaudies, Charles Pick and Anilrudh Venugopal, MD accepting advisory roles with the company....

Read More

Internal Sample Preparation, Small Size and Rapid Results Differentiate the FireflyDX Systems, says ExcitePCR’s CEO, Lyle Probst, During a BioWatch Panel

September 19, 2017

Pleasanton, Calif. and Washington, D.C. — Sept. 19, 2017 — One of the biggest barriers to delivering rapid care during an biological outbreak is about to be eliminated, said Lyle Probst, President, CEO and Founder of ExcitePCR.

When asked what makes ExcitePCR’s ...

Read More

GenomeWeb: ExcitePCR Aims to Launch Two Versions of POC MDx Platform Over Next Two Years

September 18, 2017

NEW YORK (GenomeWeb) – ExcitePCR has been developing a real-time, point-of-care technology called FireflyDX that diagnoses diseases using a wide variety of sample types and requires as little as 10 minutes for sample preparation time. 

The company is currently developing two devices based on the technology: the FireflyDX-Portable, which fits in a backpack and is planned for commercial release in summer 2018; and the FireflyDX-Handheld, which is planned for a commercial launch in 2019,  ExcitePCR CMSO David Politis said. He added that the technology will detect pathogens in situations where real-time results can prevent infectious diseases from rapidly spreading.


Read More

ExcitePCR’s CEO, Lyle Probst, Invited to Join Prestigious BioWatch Panel During Two-Day Workshop Hosted by the National Academies of Science, Engineering, and Medicine

September 06, 2017

PLEASANTON, Calif. and WASHINGTON, D.C. — Sept. 6, 2017 — Lyle Probst, ExcitePCR’s President, CEO, and founder has been invited to join a prestigious three-member BioWatch panel discussion in September about current and...

Read More

ExcitePCR Announces its FireflyDX-Portable: A Lightweight, Bookbag-sized Realtime Pathogen Detection System, with Commercial Availability Slated for Summer 2018

August 30, 2017

PLEASANTON, Calif. — August 30, 2017 — ExcitePCR™ today announced the FireflyDX-Portable™, a rechargeable bookbag-sized realtime pathogen detection system that will enable first responders, medical professionals and food safety officials to accurately obtain on-site results anywhere in the world in less than 30 minutes … including sample preparation time.


Read More

ExcitePCR Company Facts Sheet

August 30, 2017


ExcitePCR Corporation is developing portable realtime pathogen detection systems based upon superior PCR (Polymerase Chain Reaction)...

Read More

Thirty-Year Marketing Veteran, David L. Politis, Joins ExcitePCR as its Chief Marketing & Sales Officer

August 24, 2017

PLEASANTON, Calif. — August 24, 2017 — ExcitePCR today announced that David L. Politis has joined the company as its Chief Marketing & Sales Officer.

In his role as CMSO, Politis will direct and implement all marketing, sales and business development efforts for ExcitePCR as it prepares to bring to market its first commercially available...

Read More

PositiveID Successfully Detects Ebola Virus on its Firefly Dx Prototype System

August 08, 2017

DELRAY BEACH, FL August 8, 2017 – PositiveID Corporation (OTCQB: PSID), a life sciences company focused on detection and diagnostics, and its ExcitePCR Corporation subsidiary announced today that it has successfully detected Ebola virus on the Firefly Dx breadboard pathogen detection system (“prototype system”) and published a white paper and data on PositiveID’s website and ExcitePCR’s website. 

In a collaborated effort with assay partner GenArraytion Inc., ExcitePCR successfully detected Ebola virus on the Firefly Dx prototype system. Ebola virus was tested at low number of copies via polymerase chain reaction (PCR) and the amplification curves demonstrated a cycle threshold...

Read More

ExcitePCR Names Chief Science Officer

May 30, 2017

PLEASANTON, CA – ExcitePCR Corporation has named Dr. Kimothy Smith its Chief Science Officer. Dr. Smith, a recognized biodefense expert, will join Lyle Probst, the CEO of ExcitePCR, to manage the development of Firefly Dx to completion and commercialization, and execute the company’s mission under the U.S. Department of Homeland Security (“DHS”) SenseNet program to provide faster, less expensive bio-threat detection systems while providing an added level of security.  

Dr. Smith served as Senior Advisor for International Biodefense at DHS’ Office of Health Affairs and as Acting Director of the National Biosurveillance Integration Center,...

Read More

ExcitePCR Formed to Better Position Firefly Dx for $19 Billion Global Point-of-Care Diagnostics Market

May 25, 2017

PLEASANTON, CA – ExcitePCR Corporation has been formed to further the development of the Firefly Dx real-time polymerase chain reaction (PCR) breadboard prototype pathogen detection system (“Firefly Dx prototype system”) to provide greater flexibility for strategic partnership and/or financing opportunities.

The Firefly Dx prototype system is designed to be a handheld, fully automated, lab quality, real-time device able to process samples and detect pathogens at the point of need (PON) or point of care (POC), faster and less expensively than existing devices. Firefly Dx's applications include lab-quality, sample processing and detection of...

Read More